Leaderboards/Urticaria and Related Conditions

Urticaria and Related Conditions

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Yi‐Kui Xiang
Humboldt-Universität zu Berlin
2
Hanan Rashid
University Medical Center Groningen
3
Reineke Soegiharto
University Medical Center Utrecht
4
Diana Ćesić
University Hospital Centre Zagreb
5
T. Zuberbier
Humboldt-Universität zu Berlin
6
Rispa Darabadi
Hindu College of Pharmacy
7
Hanna Bonnekoh
Humboldt-Universität zu Berlin
8
John Tchen
Centre National de la Recherche Scientifique
9
Derin Karacabeyli
University of British Columbia
10
Yunxuan Lei
Shanghai Jiao Tong University

Papers

1
Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study
PLoS ONE|2024
26 cit.
2
An update on the use of antihistamines in managing chronic urticaria
Expert Opinion on Pharmacotherapy|2024
23 cit.
3
Publication in JAMA Dermatology (2024) [21 citations, W4400732620]
JAMA Dermatology|2024
21 cit.
4
Publication in Current Treatment Options in Allergy (2024) [17 citations, W4402683240]
Current Treatment Options in Allergy|2024
17 cit.
5
Publication in Allergy (2024) [16 citations, W4403215629]
Allergy|2024
16 cit.
6
Publication in Clinical & Experimental Allergy (2025) [5 citations, W4410133945]
Clinical & Experimental Allergy|2025
5 cit.
7
Publication in Current Treatment Options in Allergy (2025) [4 citations, W4410933232]
Current Treatment Options in Allergy|2025
4 cit.
8
Patients with acute and chronic spontaneous urticaria have similar autoantibody profiles: CHAPEAU pilot study
British Journal of Dermatology|2025
4 cit.
9
Publication in Current Treatment Options in Rheumatology (2025) [2 citations, W4413894708]
Current Treatment Options in Rheumatology|2025
2 cit.
10
Publication in Arthritis & Rheumatology (2025) [2 citations, W7117585509]
Arthritis & Rheumatology|2025
2 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Karsten Weller
Humboldt-Universität zu Berlin
2
Ons Mamaï
City College of San Francisco
3
Leigh Ann Jones
Society of Thoracic Surgeons
4
Reshmaa Balaji
Agency for Science, Technology and Research
5
Aristotle Lau
Cornell University
6
Patricia J. Ahl
Agency for Science, Technology and Research
7
Carine Bonnard
Agency for Science, Technology and Research
8
Keya Roy
Agency for Science, Technology and Research
9
Ildikó Szeverényi
Magyar Agrár- és Élettudományi Egyetem
10
Kim S. Robinson
University of York

Papers

1
ZAKα-driven ribotoxic stress response activates the human NLRP1 inflammasome
Science|2022
167 cit.
2
Diphtheria toxin activates ribotoxic stress and NLRP1 inflammasome-driven pyroptosis
The Journal of Experimental Medicine|2023
53 cit.
3
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results
The Journal of Allergy and Clinical Immunology In Practice|2022
39 cit.
4
Sensitivity to change and minimal clinically important difference of the angioedema control test
Clinical and Translational Allergy|2023
22 cit.
5
Urticaria Voices: Real-World Experience of Patients Living with Chronic Spontaneous Urticaria
Dermatology and Therapy|2025
21 cit.
6
Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema
Journal of Patient-Reported Outcomes|2023
17 cit.
7
Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria – Results from the validation of the Polish Urticaria Control Test
World Allergy Organization Journal|2022
11 cit.
8
Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo
JAMA Dermatology|2024
11 cit.
9
Inflammasomes in epithelial innate immunity: front line warriors
FEBS Letters|2024
10 cit.
10
Urticaria Voices: Real-World Treatment Patterns and Outcomes in Chronic Spontaneous Urticaria
Dermatology and Therapy|2025
8 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Marcus Maurer
Humboldt-Universität zu Berlin
2
Detlef Zillikens
University of Lübeck
3
David L. Sacks
National Institute of Allergy and Infectious Diseases
4
Luis A. Díaz
Memorial Sloan Kettering Cancer Center
5
Allen P. Kaplan
Medical University of South Carolina
6
K. Frank Austen
Harvard University
7
Sonja Ständer
Klinik für Schlafmedizin
8
Xinzhong Dong
Howard Hughes Medical Institute
9
Dean D. Metcalfe
National Institutes of Health
10
Yuan-Tsong Chen
National Chung Hsing University

Papers

1
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine|2015
9.4k cit.
2
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science|2017
6.6k cit.
3
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Science Translational Medicine|2014
5.1k cit.
4
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Journal of Clinical Oncology|2019
3k cit.
5
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
New England Journal of Medicine|2020
3k cit.
6
Circulating mutant DNA to assess tumor dynamics
Nature Medicine|2008
2.7k cit.
7
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Nature|2012
1.7k cit.
8
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
Nature|2002
1.7k cit.
9
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
New England Journal of Medicine|2022
1.5k cit.
10
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Proceedings of the National Academy of Sciences|2005
1.3k cit.

Reagents for Urticaria and Related Conditions

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

Phospho-Stat5 (Tyr694) (D47E7) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 700 Conjugate)

#10775$486
View Evidence →
Agilent/DakoEvidence 65

IgG

#F0202
View Evidence →
Cell Signaling TechnologyEvidence 66

c-Fos (9F6) Rabbit Monoclonal Antibody (SignalFlex™ Alexa Fluor® 700 Conjugate)

#23324$458
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Sin1 (D7G1A) Rabbit Monoclonal Antibody

#12860$161,351
View Evidence →
Agilent/Dako

C3c Complement

#F0201
View Evidence →
Cell Signaling TechnologyEvidence 67

beta-Tubulin (9F3) Rabbit Monoclonal Antibody (Alexa Fluor® 594 Conjugate)

#7634$465
View Evidence →